^
    Back
    Association details:
    Biomarker:MAF1 overexpression
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    PLoS One
    Title:

    MAF1 is a predictive biomarker in HER2 positive breast cancer

    Published date:
    10/06/2023
    Excerpt:
    MAF1 expression (probe 222998_at*) increased (Mann-Whitney test p-value = 0.0012) in response to trastuzumab treatment in HER2-positive five-year relapse-free survival breast cancer patients (ROC p-value = 2.7 x 10−6, AUC = 0.874), Fig 6B, suggesting MAF1 may be a predictive biomarker in HER2-positive breast cancer.
    DOI:
    https://doi.org/10.1371/journal.pone.0291549